• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Akoustis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    10/11/24 4:54:46 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTS alert in real time by email
    false 0001584754 0001584754 2024-10-10 2024-10-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  October 10, 2024

     

    AKOUSTIS TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or Other Jurisdiction

    of Incorporation)

    001-38029

    (Commission File

    Number)

    33-1229046

    (I.R.S. Employer

    Identification Number)

      

    9805 Northcross Center Court, Suite A

    Huntersville, NC 28078

    (Address of principal executive offices, including zip code)

     

    704-997-5735

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class:   Trading Symbol:   Name of each exchange on which registered:
    Common Stock, $0.001 par value   AKTS  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.b-2 of this chapter)

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      

    On October 10, 2024, Akoustis Technologies, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq Stock Market (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholders’ Equity Requirement”). In its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on October 8, 2024, the Company reported a stockholders’ deficit of approximately $(57.1) million and, as a result, does not satisfy the Stockholders’ Equity Requirement.

     

    As previously disclosed, Nasdaq previously notified the Company that it was not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”) and, on August 19, 2024, the Company received notice from Nasdaq indicating that the bid price for the Company’s common stock had closed at $0.10 or less per share for the 10-consecutive trading day period ended August 16, 2024. As a result, and in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Staff determined to delist the Company’s common stock from The Nasdaq Capital Market (the “Delisting Determination”).

     

    The Company appealed the Delisting Determination at a hearing (the “Hearing”) before a Nasdaq Hearings Panel (the “Panel”) on October 8, 2024. At the Hearing, the Company also presented its compliance plan to the Panel in respect of the Stockholders’ Equity Requirement.

     

    The Notice regarding the Stockholders’ Equity Requirement does not have an immediate impact on the listing of the Company’s common stock. The Company expects that the Panel’s decision following the Hearing will address the Company’s compliance with both the Bid Price Requirement and the Stockholders’ Equity Requirement.

     

    While the Panel’s determination is pending, the suspension of trading of the Company’s common stock will be stayed and the common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company any compliance period or that, in the event a compliance period is provided, that the Company will ultimately regain compliance with all applicable requirements for continued listing of its common stock on The Nasdaq Capital Market.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of federal securities laws with respect to the Company. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: the Panel’s determination following the Hearing and whether it grants the Company any period to regain compliance with the Bid Price Requirement and the Stockholders’ Equity Requirement; the Company’s ability to cure deficiencies in compliance with the Bid Price Requirement, Stockholders’ Equity Requirement and otherwise maintain compliance with other Nasdaq Listing Rules in the event it is granted a compliance period by the Panel; and risks related to the substantial costs and diversion of personnel’s attention and resources due to these matters. A delisting of the Company’s common stock from Nasdaq would materially and adversely affect its ability to raise capital and our financial condition and business. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Akoustis Technologies, Inc. 

       
    Date: October 11, 2024 By: /s/ Kenneth E. Boller
      Name: Kenneth E. Boller
      Title: Chief Financial Officer

     

     

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS

    DatePrice TargetRatingAnalyst
    3/9/2026$30.00Buy
    H.C. Wainwright
    2/3/2026$30.00Overweight
    Analyst
    2/3/2026$34.00Buy
    BofA Securities
    2/3/2026$31.00Outperform
    Leerink Partners
    2/3/2026Buy
    TD Cowen
    1/4/2024$2.00 → $1.00Overweight → Neutral
    Piper Sandler
    9/6/2023$9.25 → $1.75Buy → Neutral
    B. Riley Securities
    1/24/2023$9.25Buy
    B. Riley Securities
    More analyst ratings

    $AKTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Aktis Oncology with a new price target

    H.C. Wainwright initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $30.00

    3/9/26 9:06:39 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Aktis Oncology with a new price target

    Analyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00

    2/3/26 6:54:43 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Aktis Oncology with a new price target

    BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aktis Oncology to Present at Upcoming March Investor Conferences

    BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ETLocation: Boston, MA Leerink Partners Global Healthcare ConferenceDate & Time: Monday, March 9, 2026, at 1:40 p.m. ETLocation: Miami, FL A live w

    2/24/26 4:05:00 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

    U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administ

    2/24/26 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additi

    1/13/26 6:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 5:44:53 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 2:01:01 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/15/26 6:02:12 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AKTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Eli Lilly & Co claimed ownership of 6,344,114 shares (SEC Form 3)

    3 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/15/26 6:01:45 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/4/24 11:00:32 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    2/13/24 4:58:48 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Financials

    Live finance-specific insights

    View All

    Akoustis Reports Third Quarter FY24 Results

    Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in Next Nine MonthsRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    5/13/24 7:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET

    Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, will webcast its Q3FY24 results on Monday, May 13, 2024, at 8:00 am Eastern Time. Management will host a question-and-answer session at the end of the call. To listen to the call by telephone, please dial 877-407-3982 (domestic) or 201-493-6780 (international). The conference call will be webcast live on the Company's website and will be available for playback at the following URL: https://ir.akoustis.com/news-events/ir-calendar

    5/7/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Reports Second Quarter FY24 Results

    Q2 Revenue Up 20% Year-Over-Year, In-Line with Prior Guidance Guiding Record Quarterly Revenue for the March Quarter—Up 18 to 25% SequentiallyGrowth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in December QuarterRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    2/13/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Leadership Updates

    Live Leadership Updates

    View All

    Akoustis Announces Leadership Transition

    Charlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today the mutually agreed resignation of Jeffery B. Shealy as Chief Executive Officer and as a member of the Board of Directors, effective August 6, 2024. Kamran Cheema, the Company's Chief Product Officer, will serve as interim Chief Executive Officer. Mr. Cheema has served as Chief Product Officer for the Company since 2022

    8/8/24 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Michelle L. Petock, CEO of W Greig & Company, to its Board of Directors

    Charlotte, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has appointed Michelle L. Petock as a new member of its board of directors. The appointment brings the total number of board members to eight. Ms. Petock will serve on the Strategic Development Committee and the Audit Committee of the Company's board of directors. Jerry Neal, co-Chairman of the board, stated, "Ms. Petock is a welcome addition to our board given her extensive accomplishments in financ

    3/23/23 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Ken Boller as Chief Financial Officer

    Charlotte, N.C., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced the appointment of Ken Boller as Chief Financial Officer. Mr. Boller joined the Company in 2017 as Corporate Controller and has served in the role of Interim Chief Financial Officer since 2018. Mr. Boller will continue to operate out of the North Carolina headquarters of Akoustis and will continue to lead the finance team in the new position. Prior to Akoustis, he was a Regional Controller and Corporate Director of

    2/10/22 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care